UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 28, 2016

 


 

AEGERION PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 


 

Delaware

 

001-34921

 

20-2960116

(State or other jurisdiction
of incorporation)

 

(Commission
File No.)

 

(IRS Identification No.)

 

One Main Street, Suite 800
Cambridge, MA 02142

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (617) 500-7867

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

 

o    Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

Aegerion Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 28, 2016. At the Annual Meeting, the Company’s stockholders elected David I. Scheer, Donald K. Stern and Mary Szela as Class III directors, to serve on the Board of Directors of the Company until the Company’s 2019 Annual Meeting of Stockholders, and until their successors are duly elected and qualified. The voting results for this proposal were as follows:

 

 

 

For

 

Withheld

 

Broker Non-
Votes

 

David I. Scheer

 

17,226,069

 

2,649,678

 

5,182,332

 

Donald K. Stern

 

19,785,270

 

90,477

 

5,182,332

 

Mary Szela

 

19,472,794

 

402,953

 

5,182,332

 

 

The Company’s stockholders also voted to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016. The voting results for this proposal were as follows:

 

For

 

Against

 

Abstaining

 

Broker Non-Votes

 

24,968,196

 

84,010

 

5,873

 

0

 

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: July 5, 2016

 

 

AEGERION PHARMACEUTICALS, INC.

 

 

 

 

 

 

By:

/s/ /Gregory D. Perry

 

 

Gregory D. Perry

 

 

Chief Financial and Administrative Officer

 

3